TY - JOUR
T1 - Mars shot for nuclear medicine, molecular imaging, and molecularly targeted radiopharmaceutical therapy
AU - Wahl, Richard L.
AU - Chareonthaitawee, Panithaya
AU - Clarke, Bonnie
AU - Drzezga, Alexander
AU - Lindenberg, Liza
AU - Rahmim, Arman
AU - Thackeray, James
AU - Ulaner, Gary A.
AU - Weber, Wolfgang
AU - Zukotynski, Katherine
AU - Sunderland, John
N1 - Funding Information:
Richard Wahl is a consultant and on the scientific advisory board for Clarity Pharmaceuticals. Panithaya Chareonthaitawee is a consultant for Bioclinica, GE Healthcare, and MedTrace and receives royalties from UpToDate. Alexander Drzezga receives research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, and AVID Radiopharmaceuticals; is on the speaker honorary/advisory boards for Siemens Healthineers, Sanofi, and GE Healthcare; holds stock in Siemens Healthineers; and has a patent pending for 18F-PSMA7 (PSMA PET imaging tracer). Gary Ulaner is a consultant for Sanofi and receives grant support from Sanofi, Novartis, Genentech, and Puma Biotechnology. Wolfgang Weber is on the advisory boards of, and receives compensation from, Bayer, Blue Earth Diagnostics, Endocyte, ITM, and Pentixapharm and receives research support from BMS, ImaginAb, Ipsen, and Piramal. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - The Society of Nuclear Medicine and Molecular Imaging created the Value Initiative in 2017 as a major component of its strategic plan to further demonstrate the value of molecular imaging and molecularly targeted radiopharmaceutical therapy to patients, physicians, payers, and funding agencies. The research and discovery domain, 1 of 5 under the Value Initiative, has a goal of advancing the research and development of diagnostic and therapeutic nuclear medicine. Research and discovery efforts and achievements are essential to ensure a bright future for NM and to translate science to practice. Given the remarkable progress in the field, leaders from the research and discovery domain and society councils identified 5 broad areas of opportunity with potential for substantive growth and clinical impact. This article discusses these 5 growth areas, identifying specific areas of particularly high importance for future study and development. As there was an understanding that goals should be both visionary yet achievable, this effort was called the Mars shot for nuclear medicine.
AB - The Society of Nuclear Medicine and Molecular Imaging created the Value Initiative in 2017 as a major component of its strategic plan to further demonstrate the value of molecular imaging and molecularly targeted radiopharmaceutical therapy to patients, physicians, payers, and funding agencies. The research and discovery domain, 1 of 5 under the Value Initiative, has a goal of advancing the research and development of diagnostic and therapeutic nuclear medicine. Research and discovery efforts and achievements are essential to ensure a bright future for NM and to translate science to practice. Given the remarkable progress in the field, leaders from the research and discovery domain and society councils identified 5 broad areas of opportunity with potential for substantive growth and clinical impact. This article discusses these 5 growth areas, identifying specific areas of particularly high importance for future study and development. As there was an understanding that goals should be both visionary yet achievable, this effort was called the Mars shot for nuclear medicine.
KW - Artificial intelligence
KW - Molecular imaging
KW - Neuroimaging
KW - Radiopharmaceutical therapy
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85098676237&partnerID=8YFLogxK
U2 - 10.2967/jnumed.120.253450
DO - 10.2967/jnumed.120.253450
M3 - Article
C2 - 33334911
AN - SCOPUS:85098676237
VL - 62
SP - 6
EP - 14
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 1
ER -